Aerie PharmaceuticalsAERI today announced
top-line results from the Company's recently completed Phase 1
pharmacokinetics (PK) study, in which AR-13324 eye drops were
administered once-daily to 18 healthy individuals over an eight-day
period to assess systemic exposure to the drug. In addition to the
primary PK outcome of the study, the drug's effect on intraocular
pressure (IOP) was also measured. The completion of the PK study is an
important step in preparing for two planned Phase 3 registration studies
of AR-13324, which are expected to commence by mid-2014.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in